JPMorgan Chase & Co. set a €128.00 ($158.02) price objective on Bayer (FRA:BAYN) in a report released on Thursday, January 4th. The firm currently has a buy rating on the healthcare company’s stock.

Other equities research analysts have also issued research reports about the company. Baader Bank set a €140.00 ($172.84) price objective on Bayer and gave the stock a buy rating in a research report on Thursday, September 28th. BNP Paribas set a €130.00 ($160.49) price objective on Bayer and gave the stock a buy rating in a research report on Monday, September 25th. Warburg Research set a €121.00 ($149.38) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, September 20th. Jefferies Group set a €132.00 ($162.96) price objective on Bayer and gave the stock a buy rating in a research report on Monday, September 18th. Finally, equinet set a €118.00 ($145.68) target price on Bayer and gave the company a buy rating in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of €121.71 ($150.26).

Bayer (BAYN) traded down €0.20 ($0.25) during trading on Thursday, reaching €106.80 ($131.85). The company’s stock had a trading volume of 4,301 shares. Bayer has a 1-year low of €101.45 ($125.25) and a 1-year high of €123.82 ($152.86). The stock has a market cap of $88,400.00 and a price-to-earnings ratio of 25.25.

TRADEMARK VIOLATION WARNING: “Bayer (FRA:BAYN) Given a €128.00 Price Target at JPMorgan Chase & Co.” was published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.mareainformativa.com/jpmorgan-chase-128-00-price-target-updated-updated-updated/125122/.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.